SYSTEMATIC REVIEW article
Front. Med.
Sec. Ophthalmology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1678698
This article is part of the Research TopicNew Concepts, Advances, and Future Trends in Clinical Research on Eye DiseasesView all 65 articles
Impact of Atropine on Changes in Choroidal Thickness in Children with Myopia: A Meta-analysis of Randomized Controlled Trials
Provisionally accepted
- 1The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, China
- 2The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Atropine is used to treat myopia, and choroidal thickness (ChT) has been suggested as a biomarker for treatment response. However, randomized controlled trials (RCTs) have reported inconsistent results regarding their efficacy. This study aimed to assess the effect of atropine on ChT in children with myopia. Methods: A systematic review and meta-analysis of RCTs was conducted using PubMed, Cochrane, Embase, and Web of Science databases, including trials registered online, from inception to March 2025. Eligible studies were those that involved patients aged < 18 years with myopia treated using atropine sulfate eye drops and reported ChT outcomes. Meta-regression and the Cochrane I2 test were used to assess heterogeneity, respectively. Publication bias was evaluated using Funnel plots and Egger's and Begg's tests. Sensitivity analysis was used to examine the impact of individual studies. Results: Overall, 11 RCTs involving 1784 eyes of children with myopia were included. Four doses of atropine (0.01%, 0.025%, 0.05%, and 0.1%) were administered. Subfoveal ChT (SFChT) significantly thickened in the atropine group compared with the control group (placebo or spectacles) during the trial periods (weighted mean difference (WMD): 11.83 µm, 95% confidence interval (CI): 0.88–22.79 µm, I2 = 98.8%, P = 0.000). Additionally, 0.01% atropine showed the best effect in ChT changes at superior 1 and inferior 1 compared with control. Notably, 0.05% atropine demonstrated the most significantly thickened SFChT (WMD: 25.70 µm, 95% CI: 17.46–33.94 µm), had the best spherical equivalent control (WMD: 0.54 D, 95% CI: 0.38–0.70 D), and had the least axial length elongation (WMD: -0.21 mm, 95% CI: -0.28 to 0.14 mm). Conclusions: The results showed that atropine may increase ChT than control. Notably, 0.05% atropine may demonstrate the most favorable outcomes for ChT, spherical equivalent, and axial length.
Keywords: children with myopia, Atropine, Choroidal thickness, Meta-analysis, myopiaprogression
Received: 03 Aug 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 Liu, Tang, Zhang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chi-Xin Du, duchixin@zju.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.